Hematin therapy in porphyric attacks

C. A. Pierach, I. Bossenmaier, R. Cardinal, M. Weimer, C. J. Watson

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favorable clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.

Original languageEnglish (US)
Pages (from-to)829-832
Number of pages4
JournalKlinische Wochenschrift
Issue number16
StatePublished - Aug 1 1980


  • Hematin
  • Porphyria
  • Porphyrin precursors


Dive into the research topics of 'Hematin therapy in porphyric attacks'. Together they form a unique fingerprint.

Cite this